9211253

2 known cases. View patent page →

Cases
2
Active
0
2 closed
Filed
2019
Top venue
Fed. Cir.
1 case

Adapt Pharma Operations Ltd. v. Teva Pharmaceuticals USA, Inc.

affirmed
Docket:
20-2106
Terminated:
2022-02-10

Federal Circuit appeal from the D.N.J. Hatch-Waxman decision. The court affirmed the invalidity/obviousness holding on February 10, 2022 (Opinion by Stoll, joined by Prost; Newman dissenting). The narrative notes the appellate opinion discusses the '747 patent and does not confirm the '253 patent's role.